Prosthetic Valve Endocarditis and TAVR: though Rare, Devastating

On the bright side, the incidence of prosthetic valve endocarditis (PVE) post TAVR is not higher than post SAVR, according to this study recently presented at EuroPCR 2019, held in Paris.

There is plenty of evidence describing PVE incidence, prognosis, risk factors, etc. after surgical valve replacement surgery (SAVR). However, we know little about the causes and consequences of PVE after transcatheter aortic valve replacement (TAVR), especially at long term and in the real world.

Two registries, one from Finland and the other from Switzerland, recently presented at EuroPCR 2019, have brought up this information gap, especially now that TAVR is being increasingly used in lower risk populations with higher life expectancy. One of the factors that could contribute to the development of PVE is prosthesis dysfunction.

The retrospective analysis of Moriyama and col. looked at retrospective data from the Finn Valve registry, which included 6463 patients undergoing valve replacement (33% TAVR) between 2008 and 2017. Some 68 patients (1.05%) developed infectious PVE at mean 3.5 year-follow up (range 0 to 10 years).


Read also: Antianginal Medication Before and After Rechanneling.


Rates were similar between TAVR (0.70%; 3.4 cases per 1,000 person-years) and conventional surgery (1.22%; 2.9 cases per 1,000 person-years). According to Kaplan-Meier analysis, PVE risk at 8 years is 1.28% for TAVR vs. 1.39% for SAVR.

PVE predictors were male gender (HR: 1.73), a deep sternal wound infection or vascular access infection (HR: 5.45).

After PVE, mortality was 37.7% at one month and 52.5% at one year. Surgical treatment was independently associated with decreased in-hospital mortality (HR 0.34, CI 95% 0.21 to 0.61).

The association between PVE and vascular access site infection calls for special attention since interventional cardiologists are not as used to practicing antisepsis and asepsis as cardiovascular surgeons.


Read also: The FDA Affirms Mortality Signs with Paclitaxel Based Devices.


As for the Swedish study, it included some 4134 patients and around 103 (2.6%) developed PVE. For them, PVE predictors included kidney failure (glomerular filtration lower than 30 ml/min), transapical access site (though at present this approach is a mere anecdote), higher pre procedural valve gradient, critical pre-procedural status, higher contrast volume and atrial fibrillation.

Original Title: Prosthetic valve endocarditis after transcatheter or surgical AVR with a bioprosthetic valve: results from the FinnValve registry.

Reference: Moriyama N et al. EuroPCR 2019.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...